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Differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) remains chal-
lenging; currently the best discriminator is striatal dopaminergic imaging. However this modality fails to
identify 15e20% of DLB cases and thus other biomarkers may be useful. It is recognised electroen-
cephalography (EEG) slowing and relative medial temporal lobe preservation are supportive features of
DLB, although individually they lack diagnostic accuracy. Therefore, we investigated whether combined
EEG and MRI indices could assist in the differential diagnosis of AD and DLB.
Seventy two participants (21 Controls, 30 AD, 21 DLB) underwent resting EEG and 3 T MR imaging. Six
EEG classiﬁers previously generated using support vector machine algorithms were applied to the pre-
sent dataset. MRI index was derived from medial temporal atrophy (MTA) ratings. Logistic regression
analysis identiﬁed EEG predictors of AD and DLB. A combined EEG-MRI model was then generated to
examine whether there was an improvement in classiﬁcation compared to individual modalities.
For EEG, two classiﬁers predicted AD and DLB (model: c2 ¼ 22.1, df ¼ 2, p < 0.001, Nagelkerke
R2 ¼ 0.47, classiﬁcation ¼ 77% (AD 87%, DLB 62%)). For MRI, MTA also predicted AD and DLB (model:
c2 ¼ 6.5, df ¼ 1, p ¼ 0.01, Nagelkerke R2 ¼ 0.16, classiﬁcation ¼ 67% (77% AD, 52% DLB). However, a
combined EEG-MRI model showed greater prediction in AD and DLB (model: c2 ¼ 31.1, df ¼ 3, p < 0.001,
Nagelkerke R2 ¼ 0.62, classiﬁcation ¼ 90% (93% AD, 86% DLB)).
While suggestive and requiring validation, diagnostic performance could be improved by combining
EEG and MRI, and may represent an alternative to dopaminergic imaging.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Dementia with Lewy bodies (DLB) is the second most common
form of neurodegenerative dementia following Alzheimer's disease
(AD). However, distinguishing DLB fromAD continues to be difﬁcult
because of common and overlapping clinical and neuropathological
features (Galasko, 2001; McKeith et al., 1994), and as such, methods
which can improve their diagnostic accuracy and in turn, their
management, are of great importance.y).
r Ltd. This is an open access articlFunctional imaging approaches such as brain perfusion SPECT
studies have showed variable DLB sensitivity (64e85%) and AD
speciﬁcity (64e87%) (Colloby et al., 2008; Hanyu et al., 2006a,
2006b; Lobotesis et al., 2001; Pasquier et al., 2002; Shimizu et al.,
2005), while glucose metabolism 18F-FDG PET have similarly re-
ported varying DLB sensitivity (64e92%) and AD speciﬁcity
(65e92%) (Gilman et al., 2005; Ishii et al., 1998; Minoshima et al.,
2001). The myocardial scintigraphy SPECT tracer 123I-MIBG that
detects early disturbances of the sympathetic nervous system has
now also emerged as a promising diagnostic marker (e.g. DLB
sensitivity 69e100%, AD speciﬁcity 89%e100%) (Hanyu et al.,
2006a; Inui et al., 2014; Shimizu et al., 2016; Treglia and Cason,
2012; Yoshita et al., 2015) but needs further validation outsidee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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perhaps, the most established diagnostic tool in the differential
diagnosis of DLB and AD, where an autopsy study of conﬁrmed
cases reported DLB sensitivity 88% and non-DLB speciﬁcity 100%
(Walker et al., 2007). However FP-CIT still misses DLB cases where
there is relatively less nigrostriatal degeneration despite signiﬁcant
cortical Lewy body disease. Furthermore it is not available across all
dementia centres and is relatively expensive.
Using magnetic resonance imaging (MRI), patterns of grey
matter (GM) atrophy in AD occur predominantly in the medial
temporal lobe and temporoparietal association cortices (Burton
et al., 2002; Karas et al., 2003; Takahashi et al., 2010; Watson
et al., 2012; Whitwell et al., 2007), and the importance of medial
temporal atrophy (MTA) is reﬂected in its inclusion in the revised
diagnostic criteria for AD (Dubois et al., 2007; McKhann et al.,
2011). In DLB, while there is some degree of overlap with AD in
terms of atrophy, changes are often less diffuse and MTA is rela-
tively preserved (Burton et al., 2002; Karas et al., 2003; Takahashi
et al., 2010; Whitwell et al., 2007). Relative preservation of MTA
has now become a supportive feature of the revised consensus
criteria for DLB (McKeith et al., 2005). Assessment of MTA is
commonly undertaken by visual rating of MRI scans using the
Scheltens scale, which has emerged as a robust, quick, and clinically
applicable method of discriminating AD from normal aging and
other causes of dementia (Burton et al., 2009; Scheltens et al.,1992),
that also correlates with volumetry and AD pathology (Burton et al.,
2009). However, normal MTA scores do not exclude a diagnosis of
AD, while MTA can also occur in other dementias (Barber et al.,
1999; Bastos-Leite et al., 2007).
Electroencephalography (EEG) can also provide another means
by which to measure the wide-scale cortical disturbances that
occur in dementia and has the advantage of being non-invasive,
inexpensive, and relatively simple to use. It is recognised that
EEG slowing is among the supportive features for the diagnosis of
DLB (McKeith et al., 2005). Whilst it has been estimated that the
diagnostic accuracy of spectral and visual EEG analysis is approxi-
mately 80%, with good sensitivity, speciﬁcity remains poor
(Brenner et al., 1988) and can be inﬂuenced by other confounders
(e.g. medication, physical state etc.). Nevertheless with the advent
of semi-automated or fully automated statistical quantitative EEG
methods, which consider a range of EEG temporal and spatial fea-
tures, better delineation of DLB from AD appears possible (Bonanni
et al., 2008). However no studies have examined the combination
of multimodal approaches, particularly structural imaging and EEG
in the diagnosis of DLB. Such approaches may be advantageous in
settings where FP-CIT is not available or as an adjunct to further
clarifying the diagnosis of DLB in those with a negative FP-CIT
result.
While EEG slowing and relative preservation of the medial
temporal lobe are supportive features of DLB, individually however
they tend to lack diagnostic precision. Therefore, our objective was
to investigate the diagnostic utility of implementing combined EEG
and visual MRI indices in the differential diagnosis of AD and DLB.
Our hypothesis was that greater diagnostic accuracy between AD
and DLB would be achieved using a combinationmarker (EEG-MRI)
compared to markers from individual EEG and MRI modalities.
2. Materials and methods
2.1. Subjects
Fifty one individuals over the age of 60 (30 subjects with
probable AD (McKhann et al., 1984), 21 with probable DLB (McKeith
et al., 2005)) were recruited from a community dwelling popula-
tion of patients referred to local Old Age Psychiatry, GeriatricMedicine or Neurology Services. All subjects underwent clinical
and neuropsychological assessments. Twenty one similar aged
healthy controls were also recruited from among relatives and
friends of patients with dementia. The research was approved by
the local ethics committee. All subjects or, where appropriate, their
nearest relative, provided written informed consent. Exclusion
criteria for all subjects included contra-indications for MR imaging,
previous history of alcohol or substance misuse, signiﬁcant
neurological or psychiatric history, focal brain lesions on brain
imaging or the presence of other severe or unstable medical illness.
Assessments included the Cambridge Cognitive Examination
(CAMCOG), incorporating the Mini-Mental State Examination
(MMSE) (Folstein et al., 1975), Neuropsychiatric Inventory (NPI)
(Cummings et al., 1994) and the clinician's assessment of ﬂuctua-
tion (Walker et al., 2000). Motor parkinsonism was measured with
the Uniﬁed Parkinson's Disease Rating Scale Part III (UPDRS-III)
(Fahn, Elton and Committee, 1987).2.2. MRI
All participants underwent whole brain T1 weighted MR scan-
ning (3D MPRAGE, sagittal acquisition, matrix 216  208  180,
repetition time (TR)¼ 8.3 m, echo time (TE)¼ 4.6 m, inversion time
(TI) ¼ 1250 m, ﬂip angle ¼ 8, SENSE factor ¼ 2, voxel output
1  1  1 mm3) on a 3 T MRI system using an 8 channel head coil
(Intera Achieva scanner, Philips Medical Systems, Eindhoven,
Netherlands). The acquired volumes were angulated such that the
axial slice orientation was standardised to align with the anterior
commissure-posterior commissure (AC-PC) line.2.3. MRI visual rating
Scans were assessed by an experienced rater (RB), who was
blind to diagnoses and all clinical information. MTA was assessed
using Schelten's scale, from coronal sections of T1-weighted images
where scores for left and right hemispheres were recorded. The
scale rates medial temporal atrophy using a 5 category system ac-
cording to combination measures of the widths of the choroid
ﬁssure and temporal horn as well as the height of the hippocampal
formation (0 ¼ normal, 1 ¼ minimal, 2 ¼ mild, 3 ¼ moderate,
4 ¼ severe). Fig. 1 illustrates speciﬁc examples of bilateral MTA for
each category. Left and right scores were summed to give an overall
combined MTA score (maximum 8). Three subjects were then
randomly chosen by an independent observer and repeat mea-
surements were taken over ﬁve consecutive days by the same rater
(RB) to determine intra-observer reliability.2.4. EEG
All participants underwent high density EEG resting-state re-
cordings for a duration of 2 min and 30 s. Participants were seated
throughout the recordings and instructed to remain as still as
possible. EEG data were acquired using Wave guard caps (ANT
Neuro, Netherlands) comprising 128 sintered Ag/AgCl electrodes
placed according to the 10e5 positioning system (Oostenveld and
Praamstra, 2001). Channel signals were recorded using ASA-Lab
software (ANT Neuro, Netherlands) with a sampling frequency of
1024 Hz and electrode impedances of <5 kU. All electrodes were
referenced to Fz and a ground electrode was attached to the clav-
icle. Continuous EEG data ﬁles were saved and stored for off-line
processing. For the purposes of EEG analysis only 19 electrodes
(on the basis of the 10e20 system) were utilised: Fp1, Fp2, F3, F4,
F7, F8, Fz, T3, T4, T5, T6, C3, C4, Cz, P3, P4, Pz, O1, and O2 (Fig. 2).
Fig. 1. Coronal T1-weighted images depicting bilateral atrophy at each level of the MTA ﬁve-point scale.
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A number of EEG classiﬁers that differentiated speciﬁc pairs of
subject groups were derived from an independent Nordic based
dataset which examined 654 participants (226 healthy controls,
239 AD, 52 DLB, 147 other diagnoses), recruited from the Memory
Clinic of the Geriatric Department, National University Hospital,
Reykjavik, Iceland (Snaedal et al., 2012). In brief, classiﬁers were
generated from pairings of groups (e.g. LBD vs. AD, Controls vs. AD,
and Controls vs. LBD) in the Nordic cohort using statistical pattern
recognition (SPR). Twenty spectral features were identiﬁed as well
as 37 associated coherence features leading to a total of 1120feature extractions from each EEG recording. Classiﬁers, based on
20 of the feature extractions were obtained by comparing two
different subject groups A and B, and indexed with a score between
0 and 1; where a value close to 0 was indistinguishable from the
EEG's in group A, and a value closer to 1 was indistinguishable from
the EEGs in group B. A genetic algorithm (Engedal et al., 2015), was
then applied to select features used in the construction of the
classiﬁer for each pair of groups. The target value of the genetic
evolution of classiﬁers was the area under the receiver operating
characteristic (ROC) curve and optimisation based upon achieving a
good-to-excellent sensitivity and speciﬁcity suitable for clinical
utility. A 10-fold cross-validation approach was then used to obtain
Fig. 2. Schematic of electrode locations and features that constructed the ADms-LP classiﬁer. Arrows indicate coherences between electrodes, while stars depict single electrode
qEEG parameters.
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classiﬁer, and standard deviations were estimated from bootstrap
resampling. Six classiﬁers (Table 1) identiﬁed from this study were
then applied to our EEG dataset, and classiﬁer scores were calcu-
lated for all participants. Fig. 2 shows example EEG features that
were used to construct the moderate-severe AD vs. dementia with
Lewy bodies or Parkinson's disease dementia (ADms-LP) classiﬁer.
2.6. Statistical analyses
Data were exported into the Statistical Package for Social Sci-
ences software (SPSS ver. 22.0, http://www-01.ibm.com/software/
analytics/spss/products/statistics/) for further statistical evalua-
tion. Continuous variables were tested for normality of distribution
using the Shapiro-Wilk test and visual inspection of histograms.
Differences in demographic, clinical and imaging variables were
examined where appropriate using parametric (ANOVA) and non-
parametric (c2, Kruskal-Wallis, Mann-Whitney U) tests. Logistic
regression analyses (LRA) were conducted to investigate EEG and
MRI predictors of controls, AD and DLB. More speciﬁcally, forwardTable 1
The composition of groups in EEG based A vs. B classiﬁers.
Classiﬁer Group A Group B
NRM_CL NRM sMCI, pAD, AD, ADms, LP, VaD, FTD, DPR
sMCI_CLR sMCI pAD, AD, ADms, LP, VaD, FTD, DPR
AD_CLR pAD, AD sMCI, ADms, LP, VaD, FTD, DPR
ADms_CLR ADms sMCI, pAD, AD, LP, VaD, FTD, DPR
LP_CLR LP sMCI, pAD, AD, ADms, VaD, FTD, DPR
ADms_LP ADms LP
NRM: control; sMCI: stable mild cognitive impairment; pAD: prodromal AD; AD:
mild AD; ADms: moderate or severe AD; LP: dementia with Lewy bodies or Par-
kinson's disease dementia; VaD: vascular dementia; FTD: frontotemporal dementia;
DPR: depression; CL: all clinical groups; CLR: corresponding complement of clinical
groups.
*Detailed description of classiﬁers and group deﬁnitions are reported in Engedal
et al., (Engedal et al., 2015).stepwise approaches were used to identify the most signiﬁcant EEG
classiﬁers that predicted the groups. This involved successively
adding and then removing the EEG classiﬁers in accordance with
pre-existing statistical criteria of their parameter estimates. For
MRI and subsequent combined EEG-MRI logistic regressionmodels,
the ‘enter’ method was applied thereby including and retaining all
variables. Assuming clinical diagnosis as the ‘gold standard’, diag-
nostic characteristics of the models in distinguishing groups were
determined from ROC curves. To quantify intra-rater reliability of
MTA scores, a two-way mixed single measure intra-class correla-
tion coefﬁcient (ICC) was evaluated. A p-value of 0.05 was
considered signiﬁcant.
3. Results
3.1. Subject characteristics
Table 2 shows demographic and group characteristics. Groups
were matched for age and gender. CAMCOG andMMSE scores were
similar between AD and DLB but differed from controls. As ex-
pected, UPDRS III measures were signiﬁcantly higher in DLB than
AD and controls. NPI, NPI_hallucinations and CAF scores were all
signiﬁcantly greater in DLB than AD. The proportion of individuals
receiving cholinesterase inhibitors did not signiﬁcantly differ be-
tween dementia groups. In diagnosing DLB, 12 patients (57%) had
all 3 core symptoms of Parkinsonism, visual hallucinations and
cognitive ﬂuctuations, whereas 5 patients (24%) had 2 core symp-
toms while the remaining 4 patients (19%) had 1 core symptom but
these individuals all had a history of REM sleep behaviour disorder
(RBD). RBD was present in 16 patients with DLB (76%). Of all DLB
subjects studied, 12 had dopamine transporter 123I-FP-CIT imaging
(11 positive, 1 negative).
3.2. EEG classiﬁer scores and MTA ratings
EEG classiﬁer scores which represent the probability of a subject
Table 2
Demographic and group characteristics.
Controls AD DLB Statistic, p value
n 21 30 21
Gender (m: f) 14: 7 22: 8 15: 6 c2 ¼ 0.3, 0.9
Age (yrs.) 76.2 ± 5.3 77.4 ± 7.8 76.7 ± 6.2 F2,69 ¼ 0.2, 0.8
MMSE 77.4 ± 7.8 20.8 ± 3.9 22.4 ± 4.6 F2,69 ¼ 36.2, <0.001a
CAMCOG 77.4 ± 7.8 68.5 ± 13.6 72.3 ± 15.4 F2,69 ¼ 36.5, <0.001a
NPI_total Na 6.5 ± 6.2 10.0 ± 6.8 U49 ¼ 433.5, 0.02
NPI_hall Na 0.03 ± 0.2 1.7 ± 2.0 U49 ¼ 504.0, <0.001
UPDRS III 1.1 ± 1.4 2.5 ± 2.2 16.8 ± 8.0 H2 ¼ 47.6, <0.001b
CAF Na 0.6 ± 1.4 4.2 ± 4.2 U49 ¼ 482.5, <0.001
ChI use (y: n) Na 28: 2 19: 2 c2 ¼ 0.1, 0.7
DaTSCAN (y: n) Na Na 12: 9
Values expressed as Mean ± 1 SD.
MMSE ¼ Mini mental state examination, CAMCOG ¼ Cambridge cognitive exami-
nation, NPI_total ¼ Total neuropsychiatric inventory score, NPI_hall ¼ NPI halluci-
nations, UPDRS III ¼ Uniﬁed Parkinson's disease rating scale (Section III),
ChI ¼ Cholinesterase inhibitor, CAF ¼ Clinical assessment of ﬂuctuation, Na ¼ Not
applicable.
Bold text denotes statistical signiﬁcance.
Post Hoc tests:
a Con > AD, DLB (p < 0.001), AD vs. DLB (p  0.3) (Gabriel's).
b DLB > Con, AD (p < 0.001), Con vs. AD (p ¼ 0.2) (Mann-Whitney U).
Table 4
Frequency of summed MTA scores across groups.
Controls AD DLB Statistic, p value
n 21 30 21
MTA 1.2 ± 1.1 4.3 ± 1.9 2.9 ± 1.9 H2 ¼ 29.2, <0.001a
0e2 19 (90%) 7 (23%) 11 (52%)
3e4 2 (10%) 8 (27%) 7 (33%)
5e6 0 (0%) 12 (40%) 2 (10%)
7e8 0 (0%) 3 (10%) 1 (5%)
Values expressed as Mean ± 1 SD. MTA ¼ Medial temporal atrophy.
Values in parentheses indicate frequency expressed as percentage.
Bold text denotes statistical signiﬁcance.
Post Hoc tests:
a AD > Con (p < 0.001), DLB > Con (p ¼ 0.003), AD > DLB (p ¼ 0.03) (Mann-
Whitney U).
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ised for controls, AD and DLB (Table 3). For MTA ratings, frequency
of summed scores in controls, AD and DLB are presented in Table 4.
Signiﬁcantly higher MTA scores were observed in AD compared to
DLB and controls (p < 0.03), where the highest proportion of AD's
(40%) were rated as having ‘moderate’ MTA, while for most DLB's
(52%) and controls (90%), MTA was rated as ‘minimal’. Intra-
observer reliability was also found to be ‘excellent’ (ICC: 0.95 for
both left and right scores).Table 5
Diagnostic performance of EEG, MRI and combined EEG-MRI markers.3.3. EEG and MRI models
3.3.1. Controls vs. AD
For EEG, ‘forward stepwise’ LRA showed that ADms_CLR
(b¼ 5.2, eb¼ 172.8 (95% CI: 8.8e3375.4), Wald c2¼ 11.5, p¼ 0.001)
signiﬁcantly predicted controls and AD (model: c2 ¼ 16.6, df ¼ 1,
p < 0.001, Nagelkerke R2 ¼ 0.38, classiﬁcation accuracy ¼ 77% (Con
62%, AD 87%)). In a separate model, MTA (b ¼ 1.5, eb ¼ 4.3 (95% CI:
1.8e10.1), Wald c2 ¼ 10.7, p ¼ 0.001) also signiﬁcantly predicted
controls and AD (model: c2 ¼ 34.0, df ¼ 1, p < 0.001, Nagelkerke
R2 ¼ 0.66, classiﬁcation accuracy ¼ 82% (Con 91%, AD 77%)).
However, a combined EEG-MRI model of ADms_CLR (b ¼ 2.8,
eb ¼ 15.8 (95% CI: 0.5e525.9), Wald c2 ¼ 2.4, p ¼ 0.1) and MTA
(b ¼ 1.3, eb ¼ 3.6 (95% CI: 1.5e8.8), Wald c2 ¼ 8.0, p ¼ 0.005) was
then derived and showed superior classiﬁcation (model: c2 ¼ 36.6,
df ¼ 2, p < 0.001, Nagelkerke R2 ¼ 0.69, classiﬁcation
accuracy ¼ 90% (Con 86%, AD 93%)).Table 3
Mean scores (probabilities) of Controls, AD and DLB belonging to a particular
classiﬁer.
Classiﬁer Controls (n ¼ 21) AD (n ¼ 30) DLB (n ¼ 21)
NRM_CL 0.53 ± 0.20 0.42 ± 0.22 0.23 ± 0.24
sMCI_CLR 0.64 ± 0.15 0.50 ± 0.19 0.48 ± 0.15
AD_CLR 0.54 ± 0.18 0.43 ± 0.17 0.36 ± 0.15
ADms_CLR 0.33 ± 0.25 0.63 ± 0.22 0.72 ± 0.20
LP_CLR 0.27 ± 0.16 0.58 ± 0.19 0.74 ± 0.21
ADms_LP 0.24 ± 0.28 0.10 ± 0.09 0.37 ± 0.33
Values expressed as Mean ± 1 SD.3.3.2. AD vs. DLB
For EEG, ‘forward stepwise’ LRA revealed ADms_CLR (b ¼ 5.0,
eb ¼ 151.4 (95% CI: 1.5e15784.6), Wald c2 ¼ 4.5, p ¼ 0.03) and
ADms_LP (b ¼ 7.5, eb ¼ 1720.6 (95% CI: 15.9e186496.7), Wald
c2 ¼ 9.7, p ¼ 0.002) signiﬁcantly predicted AD and DLB (model:
c2 ¼ 22.1, df ¼ 2, p < 0.001, Nagelkerke R2 ¼ 0.47, classiﬁcation
accuracy ¼ 77% (87% AD, 62% DLB)). In a separate model, MTA was
also found to be a signiﬁcant predictor (b ¼ 0.40, eb ¼ 0.7 (95% CI:
0.5e0.9), Wald c2 ¼ 5.5, p ¼ 0.02) of AD and DLB (model: c2 ¼ 6.5,
df ¼ 1, p ¼ 0.01, Nagelkerke R2 ¼ 0.16, classiﬁcation accuracy ¼ 67%
(77% AD, 52% DLB). However, a combined EEG-MRI model of
ADms_CLR (b ¼ 6.2, eb ¼ 508.8 (95% CI: 1.4e185885.4), Wald
c2 ¼ 4.3, p ¼ 0.04), ADms_LP (b ¼ 10.2, eb ¼ 27732.5 (95% CI:
20.9e36711282.9), Wald c2 ¼ 7.8, p ¼ 0.005) and MTA (b ¼ 0.64,
eb ¼ 0.5 (95% CI: 0.3e0.9), Wald c2 ¼ 6.3, p ¼ 0.01) was then
generated that showed greater accuracy in categorising AD and DLB
(model: c2 ¼ 31.1, df ¼ 3, p < 0.001, Nagelkerke R2 ¼ 0.62, classi-
ﬁcation accuracy ¼ 90% (93% AD, 86% DLB)).3.3.3. Diagnostic utility
Diagnostic characteristics of EEG, MRI and EEG-MRI models in
controls vs. AD and AD vs. DLB are summarised in Table 5. In dis-
tinguishing controls from AD, diagnostic performance was ‘excel-
lent’ for MTA rating (ROC area 0.92), ‘good’ for EEG (ROC area 0.82)
and ‘excellent’ for the combined EEG-MRI model (ROC area 0.95).
Fig. 3A shows the ROC curves. Optimal (minimum false positive and
false negative rates) corresponded to AD sensitivity 90% and control
speciﬁcity 91% for the EEG-MRI case. In distinguishing DLB fromAD,
diagnostic accuracy was ‘moderate’ for MTA rating (ROC area 0.70),
‘good’ for EEG (ROC area 0.84) and ‘excellent’ for the combined
EEG-MRI model (ROC area 0.93). Fig. 3B depicts the ROC curves.
Optimal rates corresponded to DLB sensitivity 91% and AD speci-
ﬁcity 93% for the EEG-MRI model.ROC curve area (Area ±SE) Sensitivitya (%) Speciﬁcitya (%)
Controls vs. AD
MRI 0.92 ± 0.04 77 91
EEG 0.82 ± 0.06 70 86
EEG-MRI 0.95 ± 0.03 90 91
AD vs. DLB
MRI 0.70 ± 0.08 67 57
EEG 0.84 ± 0.06 76 77
EEG-MRI 0.93 ± 0.05 91 93
SE ¼ Standard Error.
Values in parentheses indicate occurrence expressed as percentage.
a Minimum false positive and false negative results (Maximum Youden's J
statistic).
Fig. 3. Diagnostic performance of MRI (MTA rating), EEG and combined markers in
controls vs. AD and AD vs. DLB using ROC curve analysis.
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To our knowledge this is the ﬁrst study to investigate the
implementation of combined EEG biomarkers andMRI visual rating
scores in the differential diagnosis of DLB and AD. Ourmajor ﬁnding
was that in controls vs. AD and for the clinically relevant DLB vs. AD,
a joint EEG-MRI model demonstrated greater classiﬁcation (90%)
and diagnostic accuracy compared to individual modalities.
A number of studies have now started to investigate the diag-
nostic utility of EEG in the differential diagnosis of DLB and AD.
Using structured visual rating scales, patients with DLB could be
distinguished from those with AD with sensitivity 72e79% and
speciﬁcity 76e85% (Lee et al., 2015; Roks et al., 2008). Bonanni and
colleagues also showed the potential of EEG in differentiating ADfrom DLB by application of advanced statistical methods to quan-
titative EEG measures (Bonanni et al., 2008), while others also re-
ported that EEG parameters could be used to distinguish DLB from
AD with ROC curve areas between 0.75 and 0.80 (Andersson et al.,
2008). Utilising statistical pattern recognition algorithms to
generate DLB/Parkinson's disease classiﬁers as discriminatory var-
iables, Snaedal J et al. and Engedal K et al. described excellent
diagnostic characteristics among DLB and AD (ROC area 0.97, DLB
sensitivity 93%, AD speciﬁcity 86%) and (0.92, 85%, 87%) respec-
tively (Engedal et al., 2015; Snaedal et al., 2012). The forward pro-
jection of the classiﬁers derived from Engedal et al. cohort onto our
dataset found that diagnostic measures with EEG were ‘good’ (0.84,
76%, 77%), thus further validating the use of classiﬁers as a potential
diagnostic method for differentiating DLB from AD.
For MTA ratings on MRI, signiﬁcantly higher MTA scores were
observed in AD compared to DLB and controls. The MTA proﬁle
(AD > DLB > Controls) is consistent with our previous and inde-
pendent visual rating dementia study, where MTA scores were also
found to be signiﬁcantly higher in AD and DLB compared to con-
trols as well as greater in AD than DLB (O'Donovan et al., 2013).
Using MTA scores as the discriminatory variable, diagnostic accu-
racy was ‘moderate’ (0.70, 67%, 57%) in differentiating DLB fromAD,
suggesting a supportive rather than an absolute diagnostic marker.
Combining the biomarkers of EEG andMRI resulted in enhanced
diagnostic accuracy relative to each individual modality. Of note, for
the DLB vs. AD contrast, of the 10 DLB participants incorrectly
categorised as AD byMRI, 8 were correctly classiﬁed as DLB by EEG;
while of the 8 DLBs incorrectly categorised as AD by EEG, 6 were
correctly classiﬁed as DLB by MRI. Therefore, this suggests that the
combined model appears to be harvesting, in a synergistic manner,
different elements of the AD and DLB phenotypes from EEG and
MRI, enabling relatively high diagnostic classiﬁcation. Examination
of our data suggested that MRI had a tendency to categorise AD and
DLBwith high and lowMTA respectively andwith a longer duration
of illness. In contrast, EEG largely appeared to group AD patients
with shorter duration of illness, less cognitive impairment and
relatively less MTA as well as, contrastingly, those DLB patients
with higher MTA and greater deﬁcits in global cognition. Although
requiring replication in an independent cohort, a pattern emerges
which suggests that EEG largely classify less disease progressed
patients while MRI categorises more established cases, hence, these
different modalities may be effective at different disease stages
thus allowing enhanced differential diagnostic utility when
comparing DLB and AD. However given misclassiﬁed numbers
were relatively small, and an absence of longitudinal data, our as-
sertions can only be speculative.
Strengths of the present study are: multimodal imaging and
rigorous clinical and neuropsychological data of subjects. Further-
more, EEG classiﬁers were derived from an independent cohort
enhancing their robustness as potential biomarkers. Further details
of how to obtain and implement these EEG classiﬁers can be found
using the following link (http://www.mentiscura.com/sigla/).
Weaknesses were the lack of autopsy conﬁrmed diagnoses and
relatively small patient numbers.
In conclusion, although suggestive, it appears that the diag-
nostic accuracy between DLB and AD could be enhanced by
combining EEG and MRI parameters and thus may represent
alternative or adjunctive biomarkers to dopaminergic imaging.
Further studies are warranted with large autopsy conﬁrmed pop-
ulations in order to reveal its true diagnostic extent. Whilst FP-CIT
SPECT remains the best validated imaging biomarker for DLB to
date, and so the “gold standard”, a simple EEG-MRI marker shows
promise, and, if replicated by others, may prove a useful alternative
to not only dopaminergic but to radionuclide imaging.
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